Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

in the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, RDEA684, RDEA119, RDEA806, RDEA427 and our other compounds, the timing and results of our preclinical, clinical and other studies, the sufficiency of our cash resources and our financial performance. Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs and risks related to the outcome of our business development activities, including collaboration or licensing agreements. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://www.n
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Tuesday, August 5, 2014 ... management will hold a conference call at 8:00 a.m. ... p.m., Beijing Time on August 6, 2014, to discuss ...
(Date:7/29/2014)... 29, 2014 , Next ... development program has commenced , TPM®/Oxycodone Phase ... during Q4 2014 , TPM®/Oxymorphone Phase 2 ... 1H 2015 Australian drug delivery company, Phosphagenics ... transdermal patch programs after its recent announcement of a $19.2 million ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... Fla., Sept. 27, 2011 Nuance Health today announced ... conducted on their innovative product, Swype Cold & Flu ... The clinical study, conducted on 103 volunteers ... the effectiveness, tolerability, and willingness of participants to use ...
... China, Sept. 27, 2011 /PRNewswire-Asia/ -- China Health Resource, ... Chinese Medicine (TCM) products, announced robust quarterly earnings for ... and $1.7 million in net income, 443% increase from ... of about $0.02 per share for the first half ...
Cached Medicine Technology:Swype Cold & Flu Shield Significantly Reduces Occurrence of Colds in Clinical Study 2China Health Resource, Inc. Announces Record 2nd Quarter 2011 Results 2China Health Resource, Inc. Announces Record 2nd Quarter 2011 Results 3
(Date:7/29/2014)... 2014 This Latest Guidebook for Conducting ... (2014 Edition) not only provided a comprehensive and thorough ... for imported drug registration but also introduced the practical ... guide you to use the Chinese trial venues to ... world step by step. , The audiences of this ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The ... (SQL, Nosql), Software (Database Application Builder, Data Scaling ... Models (Iaas, Paas, Dbaas) and Service Models (Public ... & Organization Size (Small And Medium, Large) - ... and segments the global cloud database and DBaaS ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... July 29, 2014 CRN International has ... Services Operation. , Christina Upton, an 11-year veteran at ... Client Services responsible for managing the day-to-day execution of ... at the center of all activities for CRN clients, ... in the world . The department interfaces directly with ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
Breaking Medicine News(10 mins):Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Cloud Database and DBaaS Market by Databases Worth $14.05 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Mortality rates increase due to extreme heat and cold 2Health News:CRN International Names New Director to Lead Client Services Department 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4
... state Health Directorate officials have confirmed that there has ... fever in about 29// villages of Nasik district. Around ... have been hospitalized. ,Malegon was the worst ... were sent to the National Institute of Virology (NIV), ...
... physician from Philadelphia has come out with a ... from arthritis. The technique when used will ease ... ,Interventional radiologist Kevin Baskin of Children's Hospital ... ankle joint of juvenile arthritis patients at the ...
... Pakistan's 155 million population carries the deadly hepatitis virus, ... ,"Hepatitis B and C is a time bomb ... to control it," said the president of the Pakistan ... 2006 report. ,The association represents medical practitioners ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... covering the provinces of Luanda, Bengo, Benguela, and Kwanza Norte. ... 13, the number of reported cases has risen to 2,026 ... Sunday WHO representative, Angola Fatoumata Diallo handed over 7 ... of Health Jose Van- Dunem. ,The National Laboratory ...
... showed that ROZEREM? (ramelteon) could be used for treating people ... reduce the time to fall asleep in adults significantly. // ... showed no signs of recurring or withdrawal effects. ... 8 mg of ROZEREM experienced at least a 50 percent ...
Cached Medicine News:Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 2Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 3Health News:ROZEREM? Can Be A Better Option For Insomnia Patients 4
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
... for screening donors on the PK7200 Automated ... CMV antigen attached to a gelatin particle ... and specificity of the CMV assay as ... respectively. The use of a gelatin particle ...
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: